Back Login to subscribe 🔔 Set Alert

NPCE Neuropace, Inc. Common Stock

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	NeuroPace To Highlight Expanding Role Of Responsive Neuromodulation In Epilepsy Care In 2026 ASSFN Meeting	75.4%
	HC Wainwright & Co. Maintains Buy on NeuroPace, Raises Price Target to $20	75.35%
	Neuropace shares are trading lower. The company reported Q1 financial results.	90.71%
	NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript	59.81%
	NeuroPace Raises FY2026 Sales Guidance from $98.000M-$100.000M to $99.000M-$101.000M vs $98.910M Est	93.31%
	NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate	79.44%
	Earnings Scheduled For May 12, 2026	91.94%